SCHEMBL25834961

SCHEMBL25834961

CC(C)C(=O)c1ccc(-c2nnc(C(C)C)o2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
NR1H4 Q96RI1 1/20 0.44
POLB P06746 1/20 0.43
HDAC6 Q9UBN7 1/20 0.41
ALDH1A1 P00352 3/20 0.41
ADCY1 Q08828 3/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 3/20 0.38
DBH P09172 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 1/20 0.37
PTPN1 P18031 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15553123 0.84 IKBKB (0.48) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL23782650 0.83 NPC1 (0.68) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL15552492 0.81 NPC1 (0.40) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL25856862 0.81 NPC1 (0.49) NPC1RAB9ANR1H4POLBALDH1A1
SCHEMBL25856874 0.79 MMP2 (0.40) NPC1RAB9ANR1H4POLBALDH1A1
SCHEMBL25856877 0.79 HDAC8 (0.46) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL25834824 0.78 TP53 (0.52) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL25835003 0.78 NOTUM (0.46) NPC1RAB9ANR1H4POLBHDAC6
SCHEMBL12126066 0.76 NOTUM (0.53) NPC1RAB9APOLBHDAC6ALDH1A1
SCHEMBL11965504 0.76 NPC1 (0.58) NPC1RAB9APOLBALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 NPC1 561/4885RAB9A 1179/4885NR1H4 296/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 NPC1 3878/4885RAB9A 977/4885NR1H4 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.